Tesofensine

Tesofensine has Phase 2 RCT-grade evidence for Obesity. Off-label / exploratory data exists for 9 additional indications (Obesity; Parkinson Disease).

Tesofensine

Research Evidence

Evidence shape

Tesofensine has Phase 2 RCT-grade evidence for Obesity. Off-label / exploratory data exists for 9 additional indications (Obesity; Parkinson Disease).

Depthhow much
12 registered trials
12 completed · 5 with posted results · combined n=196
Breadthhow many areas
10 indications mapped
9 thin / exploratory · 1 animal-only · 7 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 2
5 blinded with results · 4 distinct sponsors · AE rows aggregated from 4 trials · 3 linked publications on registered trials
Breadth and depth20 rows captured
Human
direct clinical signal
12
Animal
translational support
8
In vitro
mechanistic support
0
HighMediumLow

Anecdotal efficacy

Side effects

Clinical research side effects

Anecdotal side effects

Price

1
Peptira
US
30 mg
$119.00
$3.97/mg
2
Royal Peptides
USA/China
5 mg
$90.00
$18/mg
3
Elite Biogenix
US
1 mg
$109.99
$109.99/mg
4
Amc Essentials
US
0.5 mg
$99.99
$199.98/mg
5
Orbitrex Peptides
US
0.5 mg
$99.99
$199.98/mg
6
Eros Peptides
US
0.5 mg
$120.00
$240/mg

price offers can be sorted by column

1-6 of 10

Dosing & Protocol

How Tesofensine is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 12
Typical dose
No quantified dose captured for this tier.
Timing
unspecified
Cycle
unspecified

12 completed trials identified; trial dosing not reliably extracted from registry data.

8 sources
Clinician practice
Doctor & published-protocol guidance · n = 2
Typical dose
250 µg250 µg – 1 mg
250 µg
500 µg
1 mg
Frequency
daily
Timing
unspecified
Route
oral
Cycle
unspecified

Clinician protocols dose 250 µg–1 mg daily oral (2 sources).

2 sources
Anecdotal
Community-reported real-world use · n = 32
Typical dose
No quantified dose captured for this tier.

No structured protocol details captured for this tier yet.

Anecdotal reports primarily focus on weight loss and appetite suppression, with 29 reports indicating a 79.3% positive efficacy. A smaller number of reports (3) suggest neurological and cognitive benefits, with 100% positive feedback.

Peptide Deep Dive

Peptide Deep Dive is not projected for this peptide yet.

Peptide feedback

0 forum replies

Live community discussion for Tesofensine, shown here in the site layout and continued on the TVR forum.

Add feedback

No peptide feedback yet

Start the peptide feedback thread on the TVR forum.